drugset / Trial / NCT01855711

Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)

NCT01855711 ↗

Phase 2 Completed 32 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelTreatment

Summary

This study is an exploratory study aiming (i) to obtain clinical experience of GR68755 in Japanese subjects with severe d-IBS to explore the feasibility of the next phase study and (ii) to obtain reference data for endpoints and dosage and administration of a next phase study.

Timeline

Start
2003-09-18
Primary completion
2005-05-10
Completion
2005-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Alosetron Small molecule 1 mg —